Clinical PET Cast

Dr. Faulhaber concludes his three-part session on gynecologic oncology by examining various uterine malignancies and the disturbing fact that the incidence of cancer is increasing but is tempered by a high cure rate.

Dr. Faulhaber continues his three-part session on PET/CT and gynecologic oncology, specifically cervical cancer. The keys to cure include prevention with a vaccine, early detection, and accurate staging.

Dr. Faulhaber begins his three part series on PET/CT and gynecologic oncology by examining Medicare and Medicare Services and their recent decisions impacting gynecologic malignancies.

Dr. Faulhaber continues his two-part session by examining the impact of respiratory gating on localization, quantification, correlation, and therapy planning.

Dr. Faulhaber begins a two-part session by exploring, “Why bother doing respiratory gating?” and the refinements in PET in “stopping” the motion and seeing the lesion better.  He also discusses FDG and how imaging techniques have changed with improvements in hardware, software, and fusion.

Dr. Faulhaber explores what information (such as malignancy, grade, or previous treatment/surgery) should be specified when a clinician orders a PET, and what information (such as dose, glucose level, and type of scan) should be returned in the final PET report.

Dr. Faulhaber concludes his three part series on clinical indications by looking at diseases specific to the liver and gastrointestinal stromo tumors.

Dr. Faulhaber continues his three-part series on clinical indications by looking at PET imaging of the abdomen and comparing treatment planning pre- and post-PET.

Dr. Faulhaber begins his three part series on clinical indications by looking at diseases of the abdomen and pelvis, specifically colorectal cancer.

Dr. Faulhaber looks at the many advantages that image fusion, or PET/CT, has brought to PET, such as increased accuracy in the pinpointing of tumors.